Wenlin Lian, Shuyu Liu, Yanming Li, Lei Wang and JianBin Gong
Background and Objective: Celastrol is a pentacyclic triterpenoid with a long history of therapeutic potential. Unfortunately, their prime mechanism for myocardial infarction was unknown. Therefore, the current study has investigated celastrol’s efficiency and its cardioprotective role in isoproterenol-induced heart injury. Materials and Methods: The animals have been separated into 4 groups (n = 6). The test group was pretreated with celastrol on the 7th day at the same time as isoproterenol-induced heart damage on the 6th-7th days. The biochemical parameters were determined in serum and heart tissue homogenates. Results: Celastrol significantly decreased the myocardial infarction markers concentration in serum and increased the antioxidant concentration in isoproterenol-induced heart tissue. In addition to this, celastrol also regulates the membrane-bound as well as lysosome enzymes located in the heart tissue. Furthermore, the elevation of pro-inflammatory cytokines and NF-kB mRNA was lessened by celastrol administration. Celastrol also reduced isoproterenol-induced programmed cell death, by altering the Bcl-2, Bax and caspase-3 levels in cardiac tissue. Conclusion: Current findings suggested that administering celastrol may help to reduce cardiac damage in myocardial infarction by reducing inflammation, apoptosis and oxidative stress.
Wenlin Lian, Shuyu Liu, Yanming Li, Lei Wang and JianBin Gong, 2023. Celastrol Improves Isoproterenol-Induced Heart Failure by Reducing Inflammation, Apoptosis and Oxidative Stress. International Journal of Pharmacology, 19: 89-99.